Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA testing. In order to conserve the remaining reagent, a controlled process of batch testing was implemented. Therefore, you will likely see additional delays in receiving these supplemental test results.
Read about our plan to mitigate this on the Communications page by clicking this link: Communications
After a recent reevaluation of the Monolisa anti-HBs EIA package insert, the CTS QA/Scientific team ...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for sample...
CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...
After a thorough and comprehensive review of proposals received from suppliers of viral marker testi...